NCT07001787View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions
Dyslipidemia
Interventions
DRUG

Drug：HS-10510；

Drug：HS-10510 Description：Subjects will receive HS-10510 orally as a single and multiple ascending dose.

DRUG

Drug：Placebo

Drug：Placebo Description：Subjects will receive placebo matching the HS-10510 dose orally as a single and multiple ascending dose.

DRUG

Drug： Rosuvastatin

Drug：Rosuvastatin Description：Subjects will receive rosuvastatin orally.

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY